Drug intelligence / Profile preview

Standard of Care + ANG-3777

Development stage: Unknown
Lead developer: Elicio Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

This combination involves the standard treatment protocols for a specific condition, augmented with ANG-3777, a hepatocyte growth factor mimetic. ANG-3777 is designed to mimic the action of hepatocyte growth factor (HGF), which plays a role in tissue repair and regeneration. It is being investigated for its potential in treating acute organ injuries, including delayed graft function in kidney transplant patients and acute lung injury associated with COVID-19 pneumonia.

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on Standard of Care + ANG-3777.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Standard of Care + ANG-3777.

Explore the full profile